Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Angiomax bivalirudin: Phase IIIb/IV data

Previously reported results from the double-blind, international Phase IIIb/IV REPLACE-2 trial in 6,010 patients showed

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE